The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical development of combination therapy targeting the dominant cytokine interleukin-1β for renal cell carcinoma.
 
David Henry Aggen
Consulting or Advisory Role - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign
 
Ali Ghasemzadeh
No Relationships to Disclose
 
Wendy Mao
No Relationships to Disclose
 
Nivi Chowdhury
No Relationships to Disclose
 
Matthew Chaimowitz
No Relationships to Disclose
 
Jessica Hawley
No Relationships to Disclose
 
Vinson Wang
No Relationships to Disclose
 
Matthew Dallos
No Relationships to Disclose
 
Cheng Zhang
No Relationships to Disclose
 
Hu Li
No Relationships to Disclose
 
Xinzheng Victor Guo
No Relationships to Disclose
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc.
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc.
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)